US5206344A
(en)
*
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
CA1283046C
(en)
*
|
1986-05-29 |
1991-04-16 |
Nandini Katre |
Tumor necrosis factor formulation
|
US4745180A
(en)
*
|
1986-06-27 |
1988-05-17 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using heparin fragments
|
US5004605A
(en)
*
|
1987-12-10 |
1991-04-02 |
Cetus Corporation |
Low pH pharmaceutical compositions of recombinant β-interferon
|
US4847325A
(en)
*
|
1988-01-20 |
1989-07-11 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
IE62463B1
(en)
*
|
1988-07-07 |
1995-02-08 |
Res Dev Foundation |
Immunoconjugates for cancer diagnosis and therapy
|
US5091176A
(en)
*
|
1988-11-02 |
1992-02-25 |
W. R. Grace & Co.-Conn. |
Polymer-modified peptide drugs having enhanced biological and pharmacological activities
|
WO1990006952A1
(en)
*
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
US6166183A
(en)
*
|
1992-11-30 |
2000-12-26 |
Kirin-Amgen, Inc. |
Chemically-modified G-CSF
|
US4902502A
(en)
*
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
AU5858690A
(en)
*
|
1989-06-14 |
1991-01-08 |
Cetus Corporation |
Polymer/antibiotic conjugate
|
CA2063271A1
(en)
*
|
1989-07-14 |
1991-01-15 |
Subramonia Pillai |
Cytokine and hormone carriers for conjugate vaccines
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
Method for the production of a human recombinant tumor necrosis factor inhibitor
|
ES2069082T3
(es)
*
|
1989-08-07 |
1995-05-01 |
Debio Rech Pharma Sa |
Derivados polimericos de farmacos biologicamente activos.
|
US5393735A
(en)
*
|
1990-08-09 |
1995-02-28 |
Rohm And Haas Company |
Herbicidal glutarimides
|
US5552391A
(en)
*
|
1990-01-16 |
1996-09-03 |
La Jolla Pharmaceutical Company |
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
FR2658519B1
(fr)
*
|
1990-02-19 |
1995-07-07 |
Serbio |
Substrats peptidiques pour identification du facteur xa.
|
FR2658521B1
(fr)
*
|
1990-02-19 |
1994-01-21 |
Serbioo |
Bipeptides symetriques comportant un reste polyalkyleneglycol, procede de preparation et utilisation dans le dosage des proteases.
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5312903A
(en)
*
|
1990-06-01 |
1994-05-17 |
E. I. Du Pont De Nemours And Company |
Lysine-glycosylated recombinant interleukin-2
|
WO1996034876A1
(en)
*
|
1995-05-04 |
1996-11-07 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
US5229366A
(en)
*
|
1990-10-23 |
1993-07-20 |
Fuji Photo Film Co., Ltd. |
Peptide-containing polyethylene glycol derivatives and application thereof
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5382657A
(en)
*
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
KR100361933B1
(ko)
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
DE69334133T2
(de)
*
|
1993-09-08 |
2007-12-27 |
La Jolla Pharmaceutical Co., San Diego |
Chemisch definierten nicht-polymer wertigen Plattformmolokülen und ihren Konjugaten
|
US5880131A
(en)
*
|
1993-10-20 |
1999-03-09 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
US5446090A
(en)
*
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
US5629384A
(en)
*
|
1994-05-17 |
1997-05-13 |
Consiglio Nazionale Delle Ricerche |
Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
|
US20030053982A1
(en)
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US8071737B2
(en)
|
1995-05-04 |
2011-12-06 |
Glead Sciences, Inc. |
Nucleic acid ligand complexes
|
US5874409A
(en)
|
1995-06-07 |
1999-02-23 |
La Jolla Pharmaceutical Company |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
|
AU7071896A
(en)
*
|
1995-09-14 |
1997-04-01 |
Lxr Biotechnology Inc. |
Compositions with anti-apoptotic activity, containing a mixture of phospholipids
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
ATE342729T1
(de)
*
|
1997-01-15 |
2006-11-15 |
Phoenix Pharmacologics Inc |
Modifizierter tumor-nekrosefaktor
|
WO1998035551A1
(en)
|
1997-02-13 |
1998-08-20 |
Lxr Biotechnology Inc. |
Organ preservation solution
|
WO1999055377A2
(en)
*
|
1998-04-28 |
1999-11-04 |
Applied Research Systems Ars Holding N.V. |
Polyol-ifn-beta conjugates
|
US6858210B1
(en)
|
1998-06-09 |
2005-02-22 |
La Jolla Pharmaceutical Co. |
Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
|
US6783965B1
(en)
*
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
ES2361190T3
(es)
|
1998-08-06 |
2011-06-14 |
Mountain View Pharmaceuticals, Inc. |
Conjugados de peg-oxidasa de urato y su uso.
|
EA005005B1
(ru)
|
1998-10-16 |
2004-10-28 |
Байоджен, Инк. |
ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
|
EE04967B1
(et)
|
1998-10-16 |
2008-02-15 |
Biogen, Incorporated |
Glkoslitud interferoon-beeta, selle kasutamineja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6458953B1
(en)
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
US6399578B1
(en)
|
1998-12-09 |
2002-06-04 |
La Jolla Pharmaceutical Company |
Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
|
US7144574B2
(en)
|
1999-08-27 |
2006-12-05 |
Maxygen Aps |
Interferon β variants and conjugates
|
US6531122B1
(en)
|
1999-08-27 |
2003-03-11 |
Maxygen Aps |
Interferon-β variants and conjugates
|
US7431921B2
(en)
|
1999-08-27 |
2008-10-07 |
Maxygen Aps |
Interferon beta-like molecules
|
CZ2002521A3
(cs)
*
|
1999-08-27 |
2002-05-15 |
Maxygen Aps |
Nové molekuly podobné interferonu beta
|
TR200101086A3
(instruction)
*
|
1999-10-15 |
2001-08-21 |
|
|
CZ20021836A3
(cs)
|
1999-11-12 |
2002-08-14 |
Maxygen Holdings Ltd |
Konjugáty interferonu gama
|
US7230081B1
(en)
|
1999-11-12 |
2007-06-12 |
Maxygen Holdings, Ltd. |
Interferon gamma conjugates
|
JP2003519478A
(ja)
|
2000-01-10 |
2003-06-24 |
マキシゲン・ホールディングズ・リミテッド |
G−csf結合体
|
EP2319541A1
(en)
|
2000-02-11 |
2011-05-11 |
Bayer HealthCare LLC |
Factor VII or VIIA-like conjugates
|
US6951939B2
(en)
|
2000-06-08 |
2005-10-04 |
La Jolla Pharmaceutical Company |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
ZA200305980B
(en)
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
ATE432288T1
(de)
|
2001-02-27 |
2009-06-15 |
Maxygen Aps |
Neue interferon-beta-ähnliche moleküle
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
US7038015B2
(en)
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
JP4142569B2
(ja)
*
|
2001-06-22 |
2008-09-03 |
協和醗酵工業株式会社 |
軟膏剤
|
NZ530582A
(en)
|
2001-07-17 |
2008-06-30 |
Res Dev Foundation |
Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
|
AU2002355955A1
(en)
|
2001-08-13 |
2003-03-03 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
US7439043B2
(en)
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
EP2292273A3
(en)
|
2001-10-10 |
2011-11-23 |
BioGeneriX AG |
Remodeling and glycoconjugation of peptides
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7297511B2
(en)
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
US7226903B2
(en)
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
US7399613B2
(en)
|
2001-10-10 |
2008-07-15 |
Neose Technologies, Inc. |
Sialic acid nucleotide sugars
|
US7265085B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
EE05509B1
(et)
|
2002-01-18 |
2012-02-15 |
Biogen@Idec@Ma@Inc |
Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
|
BR0311978A
(pt)
|
2002-06-21 |
2005-03-22 |
Novo Nordisk Healthcare Ag |
Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação
|
AU2003239774A1
(en)
|
2002-07-03 |
2004-01-23 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
RS20050502A
(en)
|
2002-12-26 |
2007-08-03 |
Mountain View Pharmaceuticals Inc., |
Polymer conjugates of interferon- beta with enhanced biological potency
|
KR20060003862A
(ko)
|
2003-03-14 |
2006-01-11 |
네오스 테크놀로지스, 인크. |
수용성분기폴리머 및 그 접합체
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
US7691603B2
(en)
|
2003-04-09 |
2010-04-06 |
Novo Nordisk A/S |
Intracellular formation of peptide conjugates
|
NZ542586A
(en)
|
2003-04-09 |
2009-11-27 |
Biogenerix Ag |
Method of forming a covalent conjugate between a G-CSF peptide and PEG
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
EP2251352A1
(en)
*
|
2003-08-07 |
2010-11-17 |
ZymoGenetics, L.L.C. |
Homogeneous preparations of IL-28 and IL-29
|
EP1666496B1
(en)
|
2003-08-25 |
2014-03-12 |
Toray Industries, Inc. |
Interferon-beta composite
|
CN102516386A
(zh)
|
2003-10-10 |
2012-06-27 |
诺沃挪第克公司 |
Il-21衍生物
|
EP2633866A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
JP4719686B2
(ja)
|
2003-11-24 |
2011-07-06 |
バイオジェネリックス アーゲー |
GlycoPEG化エリスロポエチン
|
CA2553035A1
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
JP5826446B2
(ja)
|
2004-05-04 |
2015-12-02 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
O結合型糖鎖形成のポリペプチドおよび該ペプチドの製造方法
|
CN102532321B
(zh)
|
2004-06-18 |
2018-10-12 |
Ambrx公司 |
新颖抗原结合多肽和其用途
|
EP1771066A2
(en)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
|
CA2569381A1
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
WO2006031811A2
(en)
|
2004-09-10 |
2006-03-23 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
JP5948627B2
(ja)
|
2004-10-29 |
2016-07-20 |
レイショファーム ゲーエムベーハー |
線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化
|
ATE542920T1
(de)
|
2004-12-22 |
2012-02-15 |
Ambrx Inc |
Modifiziertes menschliches wachstumshormon
|
ES2449195T3
(es)
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Factor estimulante de colonias de granulocitos glicopegilado
|
US20070154992A1
(en)
|
2005-04-08 |
2007-07-05 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
US8188224B2
(en)
|
2005-04-11 |
2012-05-29 |
Savient Pharmaceuticals, Inc. |
Variant forms of urate oxidase and use thereof
|
EP1891231A4
(en)
|
2005-05-25 |
2011-06-22 |
Novo Nordisk As |
GLYCOPEGYLATED FACTOR IX
|
WO2006134173A2
(en)
|
2005-06-17 |
2006-12-21 |
Novo Nordisk Health Care Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
CN106443006A
(zh)
|
2005-11-16 |
2017-02-22 |
Ambrx公司 |
包括非天然氨基酸的方法和组合物
|
RU2322452C2
(ru)
*
|
2006-03-27 |
2008-04-20 |
Михаил Николаевич Смирнов |
Иммуномодулирующая композиция
|
RU2304586C1
(ru)
*
|
2006-03-27 |
2007-08-20 |
Михаил Николаевич Смирнов |
Препарат интерлейкина-2 и способ его получения
|
RU2008145084A
(ru)
|
2006-05-24 |
2010-06-27 |
Ново Нордиск Хелс Кеа Аг (Ch) |
Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
|
US20080248959A1
(en)
|
2006-07-21 |
2008-10-09 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
EP2069396B1
(en)
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
CA2663300C
(en)
*
|
2006-09-15 |
2014-10-07 |
Creabilis Therapeutics S.P.A. |
Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
|
JP2010505874A
(ja)
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー/エス |
ポリペプチドコンジュゲートの精製方法
|
EP2068909B1
(en)
|
2007-03-30 |
2012-04-25 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
PL2144923T3
(pl)
|
2007-04-03 |
2013-12-31 |
Biogenerix Ag |
Sposoby leczenia z użyciem glikopegilowanego G-CSF
|
CN101778859B
(zh)
|
2007-06-12 |
2014-03-26 |
诺和诺德公司 |
改良的用于生产核苷酸糖的方法
|
SI2197919T1
(sl)
|
2007-08-27 |
2014-09-30 |
Ratiopharm Gmbh |
Tekoäśa formulacija g-csf konjugata
|
EP2930182A1
(en)
|
2007-11-20 |
2015-10-14 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
BRPI0905707B1
(pt)
*
|
2008-01-18 |
2024-02-27 |
Dow Global Technologies Inc |
Método para aumentar a solubilidade aquosa de um composto ativo e composição compreendendo um composto ativo
|
SG10202011946PA
(en)
|
2008-01-22 |
2020-12-30 |
Araim Pharmaceuticals Inc |
Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
|
CN103694337B
(zh)
|
2008-02-08 |
2016-03-02 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
CN103497246B
(zh)
|
2008-02-27 |
2016-08-10 |
诺沃—诺迪斯克有限公司 |
缀合的因子viii分子
|
EP2672259A1
(en)
|
2008-05-13 |
2013-12-11 |
Advanced Liquid Logic, Inc. |
Droplet actuator devices, systems and methods
|
NZ600382A
(en)
|
2008-07-23 |
2013-11-29 |
Ambrx Inc |
Modified bovine G-CSF polypeptides and their uses
|
US9121024B2
(en)
|
2008-09-26 |
2015-09-01 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
EA019653B1
(ru)
|
2008-09-26 |
2014-05-30 |
Амбркс Инк. |
Модифицированные полипептиды эритропоэтина животных и их применение
|
AU2010265964B2
(en)
|
2009-06-25 |
2014-09-18 |
Horizon Therapeutics Usa, Inc. |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
|
CA2784800A1
(en)
|
2009-12-21 |
2011-07-21 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
EA201290541A1
(ru)
|
2009-12-21 |
2013-05-30 |
Амбркс, Инк. |
Модифицированные бычьи соматотропиновые полипептиды и их применение
|
EP2542569B1
(en)
|
2010-03-05 |
2020-09-16 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
US20120135912A1
(en)
|
2010-05-10 |
2012-05-31 |
Perseid Therapeutics Llc |
Polypeptide inhibitors of vla4
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
SI3572091T1
(sl)
|
2010-08-17 |
2024-07-31 |
Ambrx, Inc., |
Modificirani polipeptidi relaksina in njihova uporaba
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
KR102349549B1
(ko)
*
|
2010-11-12 |
2022-01-11 |
넥타르 테라퓨틱스 |
Il-2 부분 및 중합체의 접합체
|
BR112013018932B1
(pt)
|
2011-02-10 |
2020-11-17 |
Roche Glycart Ag |
polipeptídeo de interleucina-2 (il-2) mutante, imunoconjugado, polinucleotídeo isolado, célula hospedeira de microrganismos, método de produção de um polipeptídeo de il-2 mutante, composição farmacêutica e usos do polipeptídeo de il-2 mutante ou do imunoconjugado
|
AU2012280474A1
(en)
|
2011-07-01 |
2014-01-16 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
MX2014010209A
(es)
|
2012-02-29 |
2014-11-21 |
Toray Industries |
Agente inhibidor para acumulacion de fluido de la cavidad corporal.
|
JP2015512927A
(ja)
|
2012-04-16 |
2015-04-30 |
カンタブ バイオファーマシューティカルズ パテンツ リミテッド |
最適化された皮下治療薬
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
HUE043552T2
(hu)
|
2012-06-08 |
2019-09-30 |
Sutro Biopharma Inc |
Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
WO2014201378A1
(en)
*
|
2013-06-13 |
2014-12-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
PT3412302T
(pt)
|
2014-10-24 |
2021-06-09 |
Bristol Myers Squibb Co |
Polipéptidos de fgf-21 modificados e utilizações dos mesmos
|
WO2017062832A1
(en)
|
2015-10-08 |
2017-04-13 |
Nektar Therapeutics |
Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
|
WO2017189988A1
(en)
|
2016-04-29 |
2017-11-02 |
Araim Pharmaceuticals, Inc. |
Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
|
AU2018219283B2
(en)
|
2017-02-08 |
2022-05-19 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
PE20191494A1
(es)
|
2017-04-03 |
2019-10-21 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
JP7275049B2
(ja)
*
|
2017-12-27 |
2023-05-17 |
協和キリン株式会社 |
Il-2改変体
|
HRP20240016T1
(hr)
|
2018-09-11 |
2024-03-29 |
Ambrx, Inc. |
Konjugati polipeptida interleukina-2 i njihove uporabe
|
CN113366015A
(zh)
|
2018-10-19 |
2021-09-07 |
Ambrx公司 |
白细胞介素-10多肽缀合物、其二聚体及其用途
|
US20220118050A1
(en)
|
2019-01-28 |
2022-04-21 |
Toray Industries, Inc. |
Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
|
BR112021012472A2
(pt)
|
2019-01-28 |
2021-11-30 |
Toray Industries |
Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento
|
KR20210136014A
(ko)
|
2019-02-12 |
2021-11-16 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
|
EP3994169A1
(en)
|
2019-07-02 |
2022-05-11 |
F. Hoffmann-La Roche AG |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
CA3164233A1
(en)
*
|
2019-12-13 |
2021-06-17 |
Synthekine, Inc. |
Il-2 orthologs and methods of use
|
EP4117732A1
(en)
|
2020-03-11 |
2023-01-18 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
CR20220512A
(es)
|
2020-04-15 |
2022-11-07 |
Hoffmann La Roche |
Inmunoconjugados
|
MX2022014134A
(es)
|
2020-05-11 |
2022-11-30 |
Hoffmann La Roche |
Tratamiento conjunto con pbmc modificadas y un inmunoconjugado.
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
CR20230219A
(es)
|
2020-12-04 |
2023-07-07 |
Hoffmann La Roche |
Polipéptidos de interleucina-2 mutante dependientes del ph
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
WO2022212899A1
(en)
|
2021-04-03 |
2022-10-06 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
CN118215674A
(zh)
|
2021-10-14 |
2024-06-18 |
豪夫迈·罗氏有限公司 |
新颖白细胞介素-7免疫缀合物
|
JP2024537096A
(ja)
|
2021-10-14 |
2024-10-10 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための代替的なPD1-IL7vイムノコンジュゲート
|
TW202444751A
(zh)
|
2023-01-20 |
2024-11-16 |
瑞士商赫孚孟拉羅股份公司 |
重組Fc域—IL2變異體多肽及與膜錨定抗原結合多肽的組合療法
|
US12269875B2
(en)
|
2023-08-03 |
2025-04-08 |
Jeff R. Peterson |
Gout flare prevention methods using IL-1BETA blockers
|
WO2025163581A1
(en)
|
2024-02-01 |
2025-08-07 |
Astrazeneca Ab |
Cd8-binding cytokine engagers and methods of use thereof
|